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Abstract 
For live, attenuated vaccines derived from neurotropic wild-type viruses, regulatory authorities require neurovirulence safety 
testing, typically using monkeys, to assure the absence of residual neurotoxicity. Ethical concerns surrounding the use of 
nonhuman primates in product testing, coupled with questions over its predictive value, has resulted in a concerted effort to 
replace monkey-based neurovirulence safety testing with more informative, validated alternative methods that include the use of 
lower animal species (e.g., mice and rats) and/or in vitro assays such as mutation analysis by PCR and restriction enzyme 
cleavage (MAPREC). MAPREC is a WHO-approved screening tool to assess reversion to neurovirulence of oral poliovirus 
vaccine (OPV). Monitoring the genetic consistency of OPV lots by identification and quantification of the mutational profile 
using the recently developed technology of massively parallel sequencing (MPS) also holds promise not only as a replacement 
for nonhuman primate testing of OPV lots but for other vaccines for which animal-based tests are currently performed as a 
measure of manufacturing consistency and freedom of adventitious virus contamination. In many cases, the greatest hurdle to 
availability of such alternative methods has been the process rather than the science. This report summarizes the current status of 
alternative methods of neurovirulence safety testing, both those validated and those currently in development. 
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1. Use of nonhuman primates in product neurovirulence safety testing 
Live, attenuated vaccines are typically produced by repeated passage of virulent wild-type viruses under 
unnatural conditions [1]. There is no established attenuation scheme and, for most viruses, markers for attenuation 
are absent apart from the failure of a passaged isolate to produce clinical symptoms in vaccine recipients. For 
vaccines derived from neurotropic viruses, e.g., poliovirus, mumps virus, Japanese encephalitis virus, and yellow 
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fever virus, neuroattenuation must be assessed to ensure freedom of residual neurotoxicity [2]. For this reason, 
regulatory authorities require neurovirulence safety testing, typically performed in monkeys. The monkey 
neurovirulence safety test (MNVT) procedure generally involves intrathalamic or intraspinal virus inoculation of 
Macaca or Cercopithecus monkeys, followed by observations for clinical signs over a 17 to 22 day period and 
ending in euthanasia and a histopathological assessment of virus-specific lesions in brain and spinal cord tissue [3-
6]. The test is most often performed pre-licensure as one of many measures to qualify virus seeds used in vaccine 
production; however, for live oral poliovirus vaccines (OPV), the monkey neurovirulence safety test is also used 
routinely post-licensure for lot release. 
1.1. MNVT use for virus seed qualification 
For vaccine production, most manufacturers use a seed lot system in which a master virus seed stock is used to 
generate a larger working virus seed stock. A portion of the latter is then used in the vaccine manufacturing process. 
The master virus seed is qualified for neurovirulence safety in monkeys either directly, or indirectly via testing of 
the working virus seed or five consecutive bulks produced from the working virus seed. When the working virus 
seed stock is depleted (usually after many years of use), an aliquot of the qualified master virus seed is used to 
regenerate the working virus seed stock. Thus, neurovirulence safety testing of virus seeds is usually performed only 
once in the product’s lifetime and is only repeated if the master virus seed requires rederivation.   
1.2. Test use of lot release  
For OPV, in addition to testing of the three seed viruses (serotypes 1, 2 and 3) for neurovirulence safety, each 
manufactured monovalent bulk used to formulate final product is tested as well [4]. The latter requirement stems 
from concerns about virus reversion to neurovirulence, which may occur during the amplification of virus as part of 
the manufacturing process. Each produced OPV type 1, type 2, and type 3 monovalent bulk as well as reference 
preparations of the three viruses are tested in a significant number of monkeys, as described by the World Health 
Organization (WHO) [4]. As an additional precaution, the test is performed by both the manufacturer and the 
relevant national control authority.  
2. Concerns over the use of nonhuman primates in product neurovirulence safety testing 
Despite its name, there is little direct evidence to support the relevance of the MNVT for assessing the 
neurovirulence potential of viruses for humans. The one exception may be safety testing of yellow fever virus 
vaccine, in which there appears to be a correlation between MNVT data and virulence for humans [7,8]. Such a 
linkage has not been established for other viruses. This is true even in the case of poliovirus testing. Indeed, 
polioviruses found to be paralytogenic in monkeys induced no symptoms in chimpanzees [9]. Further, to date, no 
data has indicated a relationship between the relative neurovirulence of polioviruses in monkeys and the risk for 
adverse events in humans. For mumps viruses, the discordance is more apparent. In an assessment by two 
independent groups, no clinical or histopathological differences were seen between monkeys inoculated with highly 
attenuated strains and those inoculated with neurovirulent wild-type strains [10,11]. Thus, it is perhaps not entirely 
surprising that certain mumps vaccines that pass the MNVT were found to be causally associated with aseptic 
meningitis in vaccinees [12]. The relevance of the MNVT for assessing neuroattenuation of most other human 
viruses, including measles, rubella, and varicella vaccine, has not been demonstrated. Nonetheless, it is important to 
highlight the near absence of vaccine-associated clinical neurological adverse events in humans for most vaccines 
tested in monkeys, suggesting that the MNVT is not completely without merit.  
3. Animal-based alternatives to monkey neurovirulence safety testing 
3.1. Oral poliovirus vaccine (OPV) 
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While there is currently no alternative to the MNVT for qualifying OPV virus seeds for routine lot release, a 
transgenic mouse model was approved by the WHO based on studies conducted by the U.S. FDA’s Center for 
Biologics Evaluation and Research (CBER) in collaboration with other national regulatory authorities and vaccine 
manufacturers [13,14]. The mouse-based test was approved in 1999 for poliovirus type 3 and in 2000 for poliovirus 
types 1 and 2. 
3.2. Mumps vaccines 
Due to concerns over the poor reliability of the mumps virus MNVT, a rat-based assay was developed. In the 
latter, the severity of virus-induced hydrocephalus is used as a marker of virus attenuation. Contrary to results of 
testing of mumps virus strains in the MNVT, results of rat-based testing correlated well with neurovirulence 
potential for humans (Figure 1). An interlaboratory collaborative study carried out by CBER and the U.K.’s 
National Institute for Biological Standards and Control (NIBSC) showed the overall rank order of test results to be 
maintained at both study sites. In both laboratories wild-type viruses could be differentiated with statistical certainty 
from vaccine viruses, and attenuated vaccine viruses could be differentiated with statistical certainty from partially 
attenuated vaccine viruses [15]. The rat-based neurovirulence safety test for the mumps virus therefore appears to be 
robust, reproducible, and predictive. However, further validation incorporating larger studies by additional 
independent laboratories are needed in order for regulatory authorities and vaccine manufacturers to adopt the test as 




















3.3. Other vaccines 
Animal-based alternatives for the MNVT have also been developed for influenza A virus (rats), vaccinia virus-
based smallpox vaccines (mice), and yellow fever-based chimeric vaccines (mice) [16-20]. While promising, these 
assays have not been formally validated. The current status of further development of these MNVT alternatives is 
not known.  
Figure 1: Neurovirulence scores of seven different mumps virus strains as determined in monkeys (black bars) and rats (grey bars). 
Note similar scores of all virus strains in monkeys. By comparison, attenuated vaccine strains (Jeryl Lynn and RIT-4385 vaccines) in rats 
could be differentiated from insufficiently attenuated virus strains (Urabe vaccine), which then could be differentiated from wild-type virus 
strains (Lo1, 88-1961, and Kilham) or a Urabe vaccine-derived clinical isolate. 
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4. Non-animal-based alternatives to monkey neurovirulence safety testing 
By far, the vaccine for which the greatest number of animals is used in neurovirulence safety testing is OPV. As 
outlined earlier, every monovalent bulk of each of the three OPV serotypes is tested in monkeys or mice as a 
condition for lot release. It is important to distinguish here between pre-licensure preclinical neurovirulence safety 
testing from routine post-licensure lot release testing. For the former, a determination of neurovirulence safety is of 
the utmost importance; however, for the latter, one is truly interested in manufacturing consistency, for which the 
use of animals is far from ideal. For OPV, manufacturing consistency is required due to a concern over the 
accumulation of mutations during the production process, resulting in a reversion to neurovirulence. To this end, 
several groups have contributed to the identification of single base mutations associated with reversion to 
neurovirulence [21]. A molecular biology-based assay was therefore developed to quantify the frequency of these 
reversions in monovalent OPV lots. Results from this assay, termed MAPREC (mutation analysis by PCR and 
restriction enzyme cleavage), correlated well with MNVT results [22]. Its use in assessing the neurovirulence 
potential of OPV lots has been approved by the WHO.  
However, MAPREC quantifies specific, individual mutations (one per serotype). Therefore, other mutations that 
may contribute to neurovirulence would not be detected by this method. For this reason, MAPREC has not been 
approved as a replacement for animal-based testing but rather as a screening tool. That is, any lots failing MAPREC 
would be discarded and not tested in animals. To address this gap in non-animal-based alternative methods, work is 
currently being performed at CBER to exploit the recently developed technologies of massively parallel sequencing 
(MPS) for identifying and quantifying the mutational profile in OPV lots [23]. This approach may represent the 
ultimate tool for monitoring genetic consistency of live viral vaccines, holding promise not only as a replacement for 
nonhuman primate testing of OPV lots but for other vaccines for which animal-based tests are currently performed 
as a measure of manufacturing consistency and freedom from adventitious virus contamination.   
For mumps virus, studies at CBER are currently underway toward validation of a tissue culture-based assay for 
assessing virus neuroattenuation. In this assay, the growth kinetics of the test article (e.g., candidate vaccine virus 
seed) is assessed in a rat brain-derived neuronal cell line and compared to the growth kinetics of in-house reference 
standards representing sufficient and insufficiently attenuated virus strains. Preliminary studies demonstrate a very 
good correlation between virus growth kinetics in vitro and neurovirulence potential in vivo (unpublished data). 
After completion of an internal validation study, the robustness, reproducibility and predictive value of this assay 
will be formally tested through a large scale multicenter study. 
5. Validation and acceptance of alternative assays for neurovirulence safety 
Unlike the academic biomedical research setting where test methods can be readily changed, in a regulatory 
setting, changes to approved methods require labor-intensive formal validation studies, often requiring many years 
of testing. Over seven years was invested in international collaborative studies leading to validation of the transgenic 
mouse model as an alternative to the MNVT for OPV lot release [13]. Validation of the MAPREC assay and 
relevant reference materials required a similar amount of time [22,24], and the rat-based alternative to the mumps 
virus MNVT has been in the process of validation since 1999. Experience shows that the time required for assay 
validation far exceeds the time required for assay development, highlighting that the greatest impediment to 
instituting alternative methods is the process, not the science. While there is universal desire for validating 
alternative methods, this is not in the purview of manufacturers or academia. Thus, the onus often falls on the 
regulatory authorities, whose budgets are not supplemented with the funds needed to expeditiously conduct such 
studies.  
A further hindrance to the institution of alternative methods is acceptance. For example, despite having been 
validated over a decade ago, not all manufacturers have adopted the transgenic mouse-based neurovirulence safety 
test for OPV lot release. Reasons for this are multifold, ranging from a lack of willingness to develop the required 
in-house expertise to hefty submission fees required by some regulatory authorities for review of manufacturing and 
testing changes. Further, in some instances, regulatory agencies as well as manufacturers might be reluctant to 
implement alternate tests given that existing methods, even if imperfect, have historically been used with success. 
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Strategies for overcoming these hurdles, both financial and cultural, are therefore paramount in expediting the 
validation and adoption of alternative test methods that reduce, refine, and replace the use of animals. 
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